ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: New York Legislature Votes $240 Mil. Bond Issue For Roswell Park Construction; Kripke Honored

April 25, 1992

Blacks At 11% Greater Cancer Risk, 27% Higher Mortality, NCI Tell President’s Cancer Panel

March 10, 1989

Biotheraputices To Reveal Plans for Expansion

August 8, 1986

CAP, ASCCP Recommendations Standardize Lesion Terminology

July 27, 2012

High Radiation Dose Effective Ten Years After Treatment

November 28, 2003

DCCR Plans Three Multiple Contracts In Pain Control

February 17, 1978